Annovis Bio, Inc.
ANVS
$1.57
-$0.07-4.27%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 6.51M | 5.84M | 5.36M | 6.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.69M | 30.40M | 40.88M | 42.88M | 45.04M |
| Operating Income | -26.69M | -30.40M | -40.88M | -42.88M | -45.04M |
| Income Before Tax | -24.59M | -40.94M | -43.02M | -47.53M | -56.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.59 | -40.94 | -43.02 | -47.53 | -56.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.59M | -40.94M | -43.02M | -47.53M | -56.20M |
| EBIT | -26.69M | -30.40M | -40.88M | -42.88M | -45.04M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.94 | -3.76 | -4.42 | -5.04 | -6.12 |
| Normalized Basic EPS | -1.21 | -2.35 | -2.76 | -3.15 | -3.83 |
| EPS Diluted | -3.33 | -5.09 | -5.75 | -6.38 | -6.13 |
| Normalized Diluted EPS | -1.21 | -2.35 | -2.76 | -3.15 | -3.83 |
| Average Basic Shares Outstanding | 48.70M | 44.83M | 40.87M | 38.51M | 36.08M |
| Average Diluted Shares Outstanding | 48.90M | 45.03M | 41.07M | 38.71M | 36.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |